New Drug Approvals Archive - February 2017
Get news by email or subscribe to our news feeds.
February 2017
| February 1 |
Xyzal (levocetirizine dihydrochloride)
New Dosage Form Approved: January 31, 2017
Xyzal (levocetirizine dihydrochloride) FDA Approval History |
| February 2 |
New Indication Approved: February 2, 2017
Opdivo (nivolumab) FDA Approval History |
| February 7 |
Parsabiv (etelcalcetide) Injection Date of Approval: February 7, 2017
Company: Amgen Inc.
Treatment for: Secondary Hyperparathyroidism
Parsabiv (etelcalcetide) is a calcium-sensing receptor agonist indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Parsabiv (etelcalcetide) FDA Approval History |
| February 9 |
Emflaza (deflazacort) Tablets and Oral Suspension Date of Approval: February 9, 2017
Company: PTC Therapeutics, Inc.
Treatment for: Duchenne Muscular Dystrophy
Emflaza (deflazacort) is a glucocorticoid for the treatment of Duchenne Muscular Dystrophy. Emflaza (deflazacort) FDA Approval History |
| February 15 |
Siliq (brodalumab) Injection Date of Approval: February 15, 2017
Company: Valeant Pharmaceuticals International, Inc.
Treatment for: Plaque Psoriasis
Siliq (brodalumab) is a human anti-interleukin-17-receptor monoclonal antibody for the treatment of plaque psoriasis. Siliq (brodalumab) FDA Approval History |
| February 16 |
Patient Population Altered: February 15, 2017
Spiriva Respimat (tiotropium bromide) FDA Approval History |
| February 22 |
New Indication Approved: February 22, 2017
Revlimid (lenalidomide) FDA Approval History |
| February 27 |
Qtern (dapagliflozin and saxagliptin) Tablets Date of Approval: February 27, 2017
Company: AstraZeneca
Treatment for: Diabetes Type 2
Qtern (dapagliflozin and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP4) inhibitor fixed-dose combination for the treatment of adult patients with type 2 diabetes. Qtern (dapagliflozin and saxagliptin) FDA Approval History |
| February 28 |
Xermelo (telotristat ethyl) Tablets Date of Approval: February 28, 2017
Company: Lexicon Pharmaceuticals, Inc.
Treatment for: Carcinoid Syndrome Diarrhea
Xermelo (telotristat ethyl) is an oral tryptophan hydroxylase inhibitor indicated for use in combination with somatostatin analog (SSA) therapy for the treatment of carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors. Xermelo (telotristat ethyl) FDA Approval History |
New Drug Approvals Archive
2016
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2015
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2014
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2013
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2012
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2011
January,
February,
March,
April,
May,
June,
July,
August,
October,
November,
December2010
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2009
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2008
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2007
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2006
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2005
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2004
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2003
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December
